1:1 with FRAXA

Developing Arbaclofen for Fragile X – Dr. Mark Bear 1:1 with FRAXA

FRAXA Research Foundation 1:1 with FRAXA • Bear, Mark • Research Updates December 9, 2020May 21, 2021arbaclofen, baclofen

Seven years ago, arbaclofen (STX209) was pulled from development, disappointing families around the US. Now MIT professor and FRAXA Investigator Dr. Mark Bear has founded Allos Pharma to bring it back. Dr. Bear sat down with FRAXA co-founder Katie Clapp to share the story and next steps.

Yale Researcher Dr. Elizabeth Jonas 1:1 with FRAXA

FRAXA Research Foundation 1:1 with FRAXA • Jonas, Elizabeth • Research Updates September 18, 2020September 18, 2020

We talk with Dr. Elizabeth Jonas, Professor of Internal Medicine and Neurology at Yale School of Medicine, about her new research suggesting that leaky mitochondria cause some symptoms of Fragile X syndrome. Leaky membranes may also be involved in Parkinson’s Disease and other diseases.